Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Richard O Day

Showing results (11-20 of 268) with videos related to

Pageof 27
Sort By:
BMJ (Clinical Research Ed.)|June 13, 2013
Non-steroidal anti-inflammatory drugs (NSAIDs)Richard O Day, Garry G Graham
Drug Safety|January 27, 2007
Open-label extension studies: do they provide meaningful information on the safety of new drugs?Richard O Day, Kenneth M Williams
The Medical Journal of Australia|June 4, 2023
Avoiding severe drug hypersensitivity reactions: a case for HLA genotyping for at-risk patientsJana Stojanova, Richard O Day, Graeme Suthers
The Medical Journal of Australia|April 5, 2012
Time for the Pharmaceutical Benefits Advisory Committee to set its own agendaWendy L Lipworth, Ian Kerridge, Richard O Day
Emergency Medicine Australasia : EMA|June 15, 2007
Utility of urine drug screening: a clinical auditBridin P Murnion, Ron Granot, Richard O Day
Internal Medicine Journal|May 16, 2017
Life-threatening drug interactions: what the physician needs to knowRichard O Day, Leone Snowden, Andrew J McLachlan
International Journal of Medical Informatics|April 28, 2015
Identifying effective computerized strategies to prevent drug-drug interactions in hospital: A user-centered approachOlivia Missiakos, Melissa T Baysari, Richard O Day
Nature Reviews. Rheumatology|September 30, 2015
Allopurinol hypersensitivity: investigating the cause and minimizing the riskLisa K Stamp, Richard O Day, James Yun
Emergency Medicine Australasia : EMA|June 18, 2019
Role and impact of brain computed tomography in the management of drug overdoses and guideline recommendationsEmma My Tay, Paul Preisz, Richard O Day
Internal Medicine Journal|March 5, 2026
Recent Medicare rebates for key pharmacogenomic tests: advancing equitable access to prevent serious drug reactionsJana Stojanova, Jonathan Brett, Bridin Murnion, et al.
Pageof 27

Showing results (11-20 of 268) with videos related to

Sort By:
Pageof 27
BMJ (Clinical Research Ed.)|June 13, 2013
Non-steroidal anti-inflammatory drugs (NSAIDs)Richard O Day, Garry G Graham
Drug Safety|January 27, 2007
Open-label extension studies: do they provide meaningful information on the safety of new drugs?Richard O Day, Kenneth M Williams
The Medical Journal of Australia|June 4, 2023
Avoiding severe drug hypersensitivity reactions: a case for HLA genotyping for at-risk patientsJana Stojanova, Richard O Day, Graeme Suthers
The Medical Journal of Australia|April 5, 2012
Time for the Pharmaceutical Benefits Advisory Committee to set its own agendaWendy L Lipworth, Ian Kerridge, Richard O Day
Emergency Medicine Australasia : EMA|June 15, 2007
Utility of urine drug screening: a clinical auditBridin P Murnion, Ron Granot, Richard O Day
Internal Medicine Journal|May 16, 2017
Life-threatening drug interactions: what the physician needs to knowRichard O Day, Leone Snowden, Andrew J McLachlan
International Journal of Medical Informatics|April 28, 2015
Identifying effective computerized strategies to prevent drug-drug interactions in hospital: A user-centered approachOlivia Missiakos, Melissa T Baysari, Richard O Day
Nature Reviews. Rheumatology|September 30, 2015
Allopurinol hypersensitivity: investigating the cause and minimizing the riskLisa K Stamp, Richard O Day, James Yun
Emergency Medicine Australasia : EMA|June 18, 2019
Role and impact of brain computed tomography in the management of drug overdoses and guideline recommendationsEmma My Tay, Paul Preisz, Richard O Day
Internal Medicine Journal|March 5, 2026
Recent Medicare rebates for key pharmacogenomic tests: advancing equitable access to prevent serious drug reactionsJana Stojanova, Jonathan Brett, Bridin Murnion, et al.
Pageof 27